<DOC>
	<DOCNO>NCT00936611</DOCNO>
	<brief_summary>The purpose research study assess response rate LBH589 patient relapse refractory Waldenstrom 's Macroglobulinemia . LBH589 newly discover compound kill Waldenstrom cell laboratory study , however , know LBH589 show activity people Waldenstrom 's Macroglobulinemia . This drug use research treatment type cancer , multiple myeloma .</brief_summary>
	<brief_title>LBH589 Relapsed Relapsed Refractory Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>- Each cycle last 4 week ( 28 day ) . Participants take LBH589 orally day Monday , Wednesday Friday week . - While participant receive LBH589 , start study cycle , come clinic follow test procedure : physical examination , blood work EKG . - Participants may continue receive LBH589 long study doctor determines benefit .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Male female patient age 18 year old Must receive prior therapy WM , number prior therapy allow Must symptomatic relapse refractory WM Measurable monoclonal IgM protein blood presence lymphoplasmacytic cell bone marrow previous bone marrow Laboratory value describe protocol Clinically euthyroid ECOG Performance Status 2 less Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment Peripheral neuropathy CTCAE grade 2 high Impaired cardiac function clinically significant cardiac disease Impairment GI function GI disease may significantly alter absorption LBH589 Diarrhea &gt; CTCAE grade 1 Other concurrent severe and/or uncontrolled medical condition include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug Patients receive targeted agent within 2 week within 5 halflives agent active metabolite ( whichever longer ) recover side effect therapies Patients receive chemotherapy rituximab within 3 week less ; radiation therapy &gt; 30 % marrowbearing bone within 2 week less prior start study treatment ; yet recover side effect therapies Patients receive corticosteroid 2 week less prior registration . Patients may receive chronic corticosteroid give disorder Waldenstrom 's Macroglobulinemia Patients active bleeding tendency receive treatment therapeutic dos sodium warfarin coumadin derivative . Low dos Coumadin maintain line patency allow Patients undergone major surgery 4 week less prior start study drug recover side effect therapy Women pregnant breast feed woman childbearing potential use effective method birth control Male patient whose sexual partner woman childbearing potential use effective method birth control Patients prior malignancy within last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) Patients known positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>LBH589</keyword>
	<keyword>WM</keyword>
	<keyword>panobinostat</keyword>
	<keyword>relapse</keyword>
	<keyword>waldenstrom</keyword>
	<keyword>macroglobulinemia</keyword>
</DOC>